Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
DATA GRAPHICS | Product Development

How tezepelumab ranks in severe asthma subset with low eosinophils: Data Byte

March 2, 2021 1:04 AM UTC

Full data released Friday from the Phase III NAVIGATOR trial suggest tezepelumab is effective in severe asthma patients regardless of eosinophil count, but statistical significance remains to be shown.

Detailed data showed the TSLP inhibitor from partners AstraZeneca plc (LSE:AZN; NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) reduced the annualized asthma exacerbation rate (AAER) by 56% in severe asthma patients vs. placebo (p<0.001), which is slightly better than approved mAb therapies for the same population. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

Astrazeneca plc